USANA Finalizes Compensation for New CEO Kevin Guest and Outgoing CEO Jim Brown
summarizeSummary
USANA Health Sciences, Inc. filed an amendment to disclose the compensation arrangements for its new CEO, Kevin Guest, including a substantial performance-based equity award, and the severance package for former CEO Jim Brown.
check_boxKey Events
-
Former CEO Jim Brown's Transition Agreement
Jim Brown will serve as a strategic advisor until December 31, 2026, receiving an $825,000 base salary and a 2025 bonus. He will also receive a $1.5 million severance, paid in installments, and 18 months of COBRA coverage, contingent on a release of claims.
-
New CEO Kevin Guest's Compensation Package
Kevin Guest's annual base salary is set at $850,000, with a target bonus of 100% of his base salary. He will receive a $1.7 million restricted stock unit award for 2026.
-
Long-Term Performance Incentive for New CEO
Mr. Guest is eligible for a long-term performance incentive award, potentially worth up to $3.4 million, tied to the company's share price outperforming the Russell 2000 Index and achieving positive total shareholder return over a four-year period ending January 1, 2030.
auto_awesomeAnalysis
This 8-K/A filing provides crucial financial details regarding the executive transition previously announced on January 8, 2026. The company has finalized a transition agreement with former CEO Jim Brown, outlining his strategic advisor role and a $1.5 million severance package. More significantly, the filing details the comprehensive compensation for new CEO Kevin Guest, which includes a base salary, target bonus, and a substantial restricted stock unit award. A key component is a long-term performance incentive award, potentially valued up to $3.4 million, designed to align Mr. Guest's compensation with the company's share price outperformance against the Russell 2000 Index and positive total shareholder return over a four-year period. This structure aims to incentivize long-term value creation and provides clarity on the financial implications of the leadership change.
At the time of this filing, USNA was trading at $21.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $386.5M. The 52-week trading range was $18.48 to $38.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.